Matches in Wikidata for { <http://www.wikidata.org/entity/Q92380616> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- Q92380616 description "artikull shkencor i botuar më 01 janar 2019" @default.
- Q92380616 description "artículu científicu espublizáu en xineru de 2019" @default.
- Q92380616 description "bài báo khoa học" @default.
- Q92380616 description "im Januar 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92380616 description "scientific article published on 01 January 2019" @default.
- Q92380616 description "wetenschappelijk artikel" @default.
- Q92380616 description "наукова стаття, опублікована 1 січня 2019" @default.
- Q92380616 name "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 name "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 name "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 type Item @default.
- Q92380616 label "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 label "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 label "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 prefLabel "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 prefLabel "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 prefLabel "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 P1433 Q92380616-42AF8F57-9D14-4D1F-A985-56CFCFD98279 @default.
- Q92380616 P1476 Q92380616-AB55A089-26C0-4838-B7D7-B3E1FCEEA76B @default.
- Q92380616 P2093 Q92380616-23E85528-52EC-4BC9-A920-5D90B25A0F24 @default.
- Q92380616 P2093 Q92380616-5AC0C8F4-A546-48E5-B620-426FB6C11152 @default.
- Q92380616 P2093 Q92380616-60F48487-82D8-4753-A23E-F673D55BAABF @default.
- Q92380616 P2093 Q92380616-84929956-DECC-4563-942C-7D5DAC34FBB8 @default.
- Q92380616 P2093 Q92380616-A08B7AD7-F991-4673-B7F0-4F67D0BE8CB1 @default.
- Q92380616 P2093 Q92380616-C5FBB65F-1A8C-4526-A7FE-9752598CF349 @default.
- Q92380616 P2093 Q92380616-E75DF96E-3C92-4AFF-9FF3-9B0B3D1CF9D9 @default.
- Q92380616 P304 Q92380616-2B13F2CB-049E-4289-8AB8-C861C02CE6B8 @default.
- Q92380616 P31 Q92380616-3AAB26A9-BF93-446A-948D-E3A70FA96D2C @default.
- Q92380616 P356 Q92380616-C4CDBE6E-614B-4ABE-97A4-1095E9BBF077 @default.
- Q92380616 P433 Q92380616-49FAE7B2-F7AB-40BB-81A4-296EE6B30C90 @default.
- Q92380616 P478 Q92380616-F86820D2-3EAA-4D3C-B92C-F3FCAE3A2F9B @default.
- Q92380616 P50 Q92380616-0802508F-CD4A-431D-B8B2-72CF7EBC61D4 @default.
- Q92380616 P50 Q92380616-37FAF3B6-03B2-489D-9585-F0628AE3F54B @default.
- Q92380616 P50 Q92380616-3A076DF3-1939-4A20-9D90-7104D5E39FE1 @default.
- Q92380616 P50 Q92380616-6D91901B-524B-4C4A-9444-D23604B11A1A @default.
- Q92380616 P50 Q92380616-768EA682-6C7E-4F24-90CA-0E22B5F76B9B @default.
- Q92380616 P50 Q92380616-83D9BD3A-758F-44E6-9C68-F9EEF8DD3C89 @default.
- Q92380616 P50 Q92380616-8CC88D1C-68FD-473B-B1FB-F1A9E08EC6EB @default.
- Q92380616 P50 Q92380616-91A2430C-2ADD-4056-9F7E-2D242E48F326 @default.
- Q92380616 P50 Q92380616-A8C3AD22-066C-49CB-B46A-64BD84245D84 @default.
- Q92380616 P50 Q92380616-ABAE936F-9ACE-4D40-B79F-B1E558006539 @default.
- Q92380616 P50 Q92380616-FE32E530-D305-4CD9-83FC-6E0469E97805 @default.
- Q92380616 P577 Q92380616-6F0BC77A-1C2F-4B30-8B8A-6E673F52CE8F @default.
- Q92380616 P698 Q92380616-006945BB-7DDC-4211-ADB4-092A9209D46D @default.
- Q92380616 P921 Q92380616-12CCC4A7-60EC-49FB-9CAE-36BD5AD429C3 @default.
- Q92380616 P921 Q92380616-73702F65-D369-4064-8C72-2C87EF4C2BFF @default.
- Q92380616 P356 IMP3302 @default.
- Q92380616 P698 30873953 @default.
- Q92380616 P1433 Q4775353 @default.
- Q92380616 P1476 "Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP" @default.
- Q92380616 P2093 "Ahmed M Bayoumi" @default.
- Q92380616 P2093 "Alex Wong" @default.
- Q92380616 P2093 "Canadian Observational Cohort Collaboration" @default.
- Q92380616 P2093 "Jaime Younger" @default.
- Q92380616 P2093 "Julio Montaner" @default.
- Q92380616 P2093 "Mark Hull" @default.
- Q92380616 P2093 "Rejean Thomas" @default.
- Q92380616 P304 "211-220" @default.
- Q92380616 P31 Q13442814 @default.
- Q92380616 P356 "10.3851/IMP3302" @default.
- Q92380616 P433 "3" @default.
- Q92380616 P478 "24" @default.
- Q92380616 P50 Q104537107 @default.
- Q92380616 P50 Q114416770 @default.
- Q92380616 P50 Q37837778 @default.
- Q92380616 P50 Q56613744 @default.
- Q92380616 P50 Q72252101 @default.
- Q92380616 P50 Q73255448 @default.
- Q92380616 P50 Q88325567 @default.
- Q92380616 P50 Q89094959 @default.
- Q92380616 P50 Q91076503 @default.
- Q92380616 P50 Q91380115 @default.
- Q92380616 P50 Q92586267 @default.
- Q92380616 P577 "2019-01-01T00:00:00Z" @default.
- Q92380616 P698 "30873953" @default.
- Q92380616 P921 Q155954 @default.
- Q92380616 P921 Q422604 @default.